DK2498756T3 - Tabletformuleringer af neratinibmaleat - Google Patents

Tabletformuleringer af neratinibmaleat Download PDF

Info

Publication number: DK2498756T3
Authority: DK; Denmark
Prior art keywords: neratinibmaleate; tablet formulations; formulations; tablet
Prior art date: 2009-11-09

Application number

DK10779339T

Other languages

English (en)

Other versions

DK2498756T4 (da

Inventor

Muhammad Ashraf

Krishnendu Ghosh

Chimanlall Goolcharran

Mainuddin Mahmud

Arwinder Singh Nagi

Original Assignee

Wyeth Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-09

Filing date

2010-11-02

Publication date

2019-11-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2498756(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-11-02 Application filed by Wyeth Llc filed Critical Wyeth Llc

2019-11-25 Publication of DK2498756T3 publication Critical patent/DK2498756T3/da

2023-03-20 Application granted granted Critical

2023-03-20 Publication of DK2498756T4 publication Critical patent/DK2498756T4/da

Links

VXZCUHNJXSIJIM-MEBGWEOYSA-N (z)-but-2-enedioic acid;(e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound OC(=O)\C=C/C(O)=O.C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 VXZCUHNJXSIJIM-MEBGWEOYSA-N 0.000 title 1
229950008835 neratinib Drugs 0.000 title 1
239000007916 tablet composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK10779339.0T 2009-11-09 2010-11-02 Tabletformuleringer af neratinibmaleat DK2498756T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25940309P	2009-11-09	2009-11-09
PCT/IB2010/054964 WO2011055303A1 (en)	2009-11-09	2010-11-02	Tablet formulations of neratinib maleate

Publications (2)

Publication Number	Publication Date
DK2498756T3 true DK2498756T3 (da)	2019-11-25
DK2498756T4 DK2498756T4 (da)	2023-03-20

Family

ID=43478191

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK22169771.7T DK4066821T3 (da)	2009-11-09	2010-11-02	Tabletformuleringer af neratinibmaleat
DK10779339.0T DK2498756T4 (da)	2009-11-09	2010-11-02	Tabletformuleringer af neratinibmaleat

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK22169771.7T DK4066821T3 (da)	2009-11-09	2010-11-02	Tabletformuleringer af neratinibmaleat

Country Status (23)

Country	Link
US (2)	US8518446B2 (da)
EP (4)	EP4570242A3 (da)
JP (3)	JP5835883B2 (da)
CN (2)	CN103893140B (da)
AR (2)	AR078952A1 (da)
AU (1)	AU2010316683B2 (da)
CA (1)	CA2780428C (da)
CY (1)	CY1122330T1 (da)
DK (2)	DK4066821T3 (da)
ES (3)	ES2757882T5 (da)
FI (3)	FI2498756T4 (da)
FR (1)	FR25C1035I1 (da)
HR (2)	HRP20250604T1 (da)
HU (3)	HUE071632T2 (da)
LT (3)	LT2498756T (da)
NZ (1)	NZ599763A (da)
PL (2)	PL2498756T5 (da)
PT (2)	PT2498756T (da)
RS (2)	RS66797B1 (da)
SI (2)	SI2498756T2 (da)
SM (2)	SMT202500153T1 (da)
TW (1)	TWI466690B (da)
WO (1)	WO2011055303A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10351448A1 (de) *	2003-11-04	2005-06-09	Bayer Healthcare Ag	Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
CN113952459B (zh)	2005-02-03	2025-02-11	综合医院公司	治疗吉非替尼耐药性癌症的方法
CN103110948A (zh)	2005-11-04	2013-05-22	惠氏公司	mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (zh)	2008-06-17	2012-08-22	惠氏有限责任公司	含有hki-272和长春瑞滨的抗肿瘤组合
HUE032958T2 (hu)	2008-08-04	2017-11-28	Wyeth Llc	4-Anilino-3-ciano-kinolinok és capecitabin antineoplasztikus kombinációi
LT3000467T (lt)	2009-04-06	2023-04-11	Wyeth Llc	Krūties vėžio gydymo schema naudojant neratinibą
DK4066821T3 (da) *	2009-11-09	2025-04-14	Wyeth Llc	Tabletformuleringer af neratinibmaleat
EP2498751B1 (en) *	2009-11-09	2019-04-03	Wyeth LLC	Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
WO2013102145A1 (en)	2011-12-28	2013-07-04	Global Blood Therapeutics, Inc.	Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
JP6242810B2 (ja)	2011-12-28	2017-12-06	グローバル・ブラッド・セラピューティクス・インコーポレイテッドＧｌｏｂａｌＢｌｏｏｄＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	置換ベンズアルデヒド化合物および組織酸素化の増加におけるそれらの使用方法
US9458139B2 (en)	2013-03-15	2016-10-04	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
CN105246477A (zh)	2013-03-15	2016-01-13	全球血液疗法股份有限公司	化合物及其用于调节血红蛋白的用途
US8952171B2 (en)	2013-03-15	2015-02-10	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
EA037091B1 (ru)	2013-03-15	2021-02-04	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
US10266551B2 (en)	2013-03-15	2019-04-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
MX379228B (es)	2013-03-15	2025-03-10	Global Blood Therapeutics Inc	Compuestos y usos de estos para la modulación de la hemoglobina.
US9818967B2 (en) *	2013-06-28	2017-11-14	Universal Display Corporation	Barrier covered microlens films
CN104337782A (zh) *	2013-08-02	2015-02-11	山东新时代药业有限公司	一种甲磺酸伊马替尼片剂
EA201992707A1 (ru)	2013-11-18	2020-06-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
EP3097108B8 (en)	2014-01-23	2021-04-07	Immunolight, LLC	Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders
CN114213390A (zh)	2014-02-07	2022-03-22	全球血液疗法股份有限公司	一种化合物的结晶多晶型物
ES2805008T3 (es)	2014-02-17	2021-02-10	Childrens Nat Medical Ct	Procedimiento y sistema para proporcionar recomendaciones para la ejecución óptima de procedimientos quirúrgicos
SG10201900648SA (en)	2014-07-25	2019-02-27	Novartis Ag	Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
US10016471B2 (en)	2015-06-29	2018-07-10	Phloronol, Inc.	Solid pharmaceutical compositions of brown algae
FI3383392T3 (fi)	2015-12-04	2025-09-11	Global Blood Therapeutics Inc	Annosteluohjelmat 2-hydroksi-6-((2-(1-isopropyyli-1h-pyratsol-5-yyli)pyridin-3-yyli)metoksi)bentsaldehydille
CN106831710A (zh) *	2015-12-07	2017-06-13	常州爱诺新睿医药技术有限公司	一种无定型来那替尼或其药学上可接受的盐与药用辅料的固体分散体及其制备方法
CN106913529B (zh) *	2015-12-24	2020-12-04	江苏恒瑞医药股份有限公司	一种来那替尼或其可药用盐药物组合物的制备方法
CA2937365C (en) *	2016-03-29	2018-09-18	F. Hoffmann-La Roche Ag	Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI752307B (zh)	2016-05-12	2022-01-11	美商全球血液治療公司	新穎化合物及製造化合物之方法
KR102498693B1 (ko) *	2016-09-07	2023-02-10	셀진 코포레이션	정제 조성물
TWI778983B (zh) *	2016-10-12	2022-10-01	美商全球血液治療公司	包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
CA3060316A1 (en) *	2017-04-28	2018-11-01	Asana Biosciences, Llc	Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
CA3079916A1 (en) *	2017-10-24	2019-05-02	Jiangsu Hengrui Medicine Co., Ltd.	Pharmaceutical composition containing quinoline derivative
WO2020072377A1 (en)	2018-10-01	2020-04-09	Global Blood Therapeutics, Inc.	Modulators of hemoglobin for the treatment of sickle cell disease
IL295007A (en)	2020-01-31	2022-09-01	Nanocopoeia Llc	Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) *	2020-04-30	2021-11-04	Nanocopoeia, Llc	Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
US20220378788A1 (en) *	2020-04-30	2022-12-01	Nanocopoeia, Llc	Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof
JP2023531606A (ja) *	2020-06-19	2023-07-25	アセルタ・ファーマ・ベスローテン・フェンノートシャップ	アカラブルチニブマレイン酸塩剤形
CN116211859A (zh) *	2021-12-03	2023-06-06	江苏奥赛康药业有限公司	一种含有马来酸奈拉替尼的药用组合物及其制备方法
IL315415A (en) *	2022-03-07	2024-11-01	Janssen Pharmaceuticals Inc	The compositions containing eticarpant
WO2023172958A1 (en) *	2022-03-08	2023-09-14	Onkosxcel Therapeutics, Llc	Stable formulations of talabostat
WO2024187321A1 (zh)	2023-03-10	2024-09-19	甫康（上海）健康科技有限责任公司	含有egfr抑制剂的药物组合物及其制备方法和应用
CN117427076B (zh) *	2023-12-05	2025-09-19	中国科学技术大学	来那替尼在制备预防或治疗动脉粥样硬化药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW442301B (en) *	1995-06-07	2001-06-23	Sanofi Synthelabo	Pharmaceutical compositions containing irbesartan
US6002008A (en)	1997-04-03	1999-12-14	American Cyanamid Company	Substituted 3-cyano quinolines
US6288082B1 (en)	1998-09-29	2001-09-11	American Cyanamid Company	Substituted 3-cyanoquinolines
US6297258B1 (en)	1998-09-29	2001-10-02	American Cyanamid Company	Substituted 3-cyanoquinolines
US6384051B1 (en)	2000-03-13	2002-05-07	American Cyanamid Company	Method of treating or inhibiting colonic polyps
US7399865B2 (en) *	2003-09-15	2008-07-15	Wyeth	Protein tyrosine kinase enzyme inhibitors
US20050142192A1 (en) *	2003-10-15	2005-06-30	Wyeth	Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
AR046544A1 (es) *	2003-10-15	2005-12-14	Wyeth Corp	Administracion oral de acido [2- (8,9 - dioxo - 2,6 - diazabiciclo [5.2.0] non -1 (7) - en - 2 - il ) alquil] fosfonico yderivados
CN101039952A (zh) *	2004-10-13	2007-09-19	惠氏公司	作为pi3k抑制剂的17－羟基渥曼青霉素类似物
US20080268034A1 (en)	2005-01-07	2008-10-30	Girish Karanth	Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
ES2340610T3 (es) *	2005-04-28	2010-06-07	Wyeth Llc	Composiciones de tanaproget micronizado y procedimientos de preparacion de las mismas.
EP1948180B1 (en) *	2005-11-11	2013-03-13	Boehringer Ingelheim International GmbH	Combination treatment of cancer comprising egfr/her2 inhibitors
JP2007169273A (ja) *	2005-11-28	2007-07-05	Takeda Chem Ind Ltd	杵付着を改善した医薬製剤
JP2007211005A (ja) *	2006-01-16	2007-08-23	Ono Pharmaceut Co Ltd	固形製剤用組成物および固形製剤
TW200806282A (en) *	2006-05-05	2008-02-01	Wyeth Corp	Solid dosage formulations
MX2009007254A (es) *	2007-01-12	2009-08-12	Wyeth Corp	Composiciones de tableta en tableta.
ES2639854T3 (es) *	2007-02-01	2017-10-30	Takeda Pharmaceutical Company Limited	Preparación de comprimidos sin causar problemas de fabricación de comprimidos
JP2009089982A (ja) *	2007-10-11	2009-04-30	Ohara Yakuhin Kogyo Kk	打錠用造粒物の造粒方法
WO2009100176A2 (en) *	2008-02-07	2009-08-13	Abbott Laboratories	Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP2448563A2 (en) *	2009-07-02	2012-05-09	Wyeth LLC	3-cyanoquinoline tablet formulations and uses thereof
DK4066821T3 (da) *	2009-11-09	2025-04-14	Wyeth Llc	Tabletformuleringer af neratinibmaleat

2010
- 2010-11-02 DK DK22169771.7T patent/DK4066821T3/da active
- 2010-11-02 LT LT10779339T patent/LT2498756T/lt unknown
- 2010-11-02 PL PL10779339.0T patent/PL2498756T5/pl unknown
- 2010-11-02 HU HUE22169771A patent/HUE071632T2/hu unknown
- 2010-11-02 AU AU2010316683A patent/AU2010316683B2/en active Active
- 2010-11-02 ES ES10779339T patent/ES2757882T5/es active Active
- 2010-11-02 NZ NZ599763A patent/NZ599763A/en unknown
- 2010-11-02 WO PCT/IB2010/054964 patent/WO2011055303A1/en not_active Ceased
- 2010-11-02 HU HUE10779339A patent/HUE046606T2/hu unknown
- 2010-11-02 SI SI201031952T patent/SI2498756T2/sl unknown
- 2010-11-02 ES ES22169771T patent/ES3029208T3/es active Active
- 2010-11-02 HR HRP20250604TT patent/HRP20250604T1/hr unknown
- 2010-11-02 DK DK10779339.0T patent/DK2498756T4/da active
- 2010-11-02 EP EP25160646.3A patent/EP4570242A3/en active Pending
- 2010-11-02 PT PT107793390T patent/PT2498756T/pt unknown
- 2010-11-02 FI FIEP10779339.0T patent/FI2498756T4/fi active
- 2010-11-02 LT LTEP22169771.7T patent/LT4066821T/lt unknown
- 2010-11-02 CN CN201410082103.7A patent/CN103893140B/zh active Active
- 2010-11-02 HR HRP20192026TT patent/HRP20192026T4/hr unknown
- 2010-11-02 EP EP19154710.8A patent/EP3566697B1/en active Active
- 2010-11-02 PT PT221697717T patent/PT4066821T/pt unknown
- 2010-11-02 RS RS20250477A patent/RS66797B1/sr unknown
- 2010-11-02 EP EP22169771.7A patent/EP4066821B1/en active Active
- 2010-11-02 SI SI201032155T patent/SI4066821T1/sl unknown
- 2010-11-02 SM SM20250153T patent/SMT202500153T1/it unknown
- 2010-11-02 RS RS20191417A patent/RS59599B2/sr unknown
- 2010-11-02 CN CN201080060546.6A patent/CN102724970B/zh active Active
- 2010-11-02 EP EP10779339.0A patent/EP2498756B2/en active Active
- 2010-11-02 PL PL22169771.7T patent/PL4066821T3/pl unknown
- 2010-11-02 FI FIEP22169771.7T patent/FI4066821T3/fi active
- 2010-11-02 SM SM20190632T patent/SMT201900632T1/it unknown
- 2010-11-02 CA CA2780428A patent/CA2780428C/en active Active
- 2010-11-02 ES ES19154710T patent/ES2998766T3/es active Active
- 2010-11-05 US US12/940,808 patent/US8518446B2/en active Active
- 2010-11-08 JP JP2010249385A patent/JP5835883B2/ja active Active
- 2010-11-08 TW TW99138396A patent/TWI466690B/zh active
- 2010-11-09 AR ARP100104156A patent/AR078952A1/es not_active Application Discontinuation
2013
- 2013-08-21 US US13/972,764 patent/US8790708B2/en active Active
2015
- 2015-02-06 JP JP2015021870A patent/JP2015091882A/ja not_active Withdrawn
2017
- 2017-02-06 JP JP2017019429A patent/JP2017075192A/ja not_active Withdrawn
2018
- 2018-11-14 AR ARP180103329A patent/AR114143A2/es not_active Application Discontinuation
2019
- 2019-11-14 CY CY20191101200T patent/CY1122330T1/el unknown
2025
- 2025-08-21 HU HUS2500035C patent/HUS2500035I1/hu unknown
- 2025-08-25 LT LTPA2025531C patent/LTPA2025531I1/lt unknown
- 2025-08-29 FI FIC20250029C patent/FIC20250029I1/fi unknown
- 2025-09-04 FR FR25C1035C patent/FR25C1035I1/fr active Active

Also Published As

Publication number	Publication date
LT2498756T (lt)	2019-12-10
SMT202500153T1 (it)	2025-05-12
HUS2500035I1 (hu)	2025-09-28
TW201138774A (en)	2011-11-16
EP2498756A1 (en)	2012-09-19
CY1122330T1 (el)	2021-01-27
SI4066821T1 (sl)	2025-06-30
CN103893140B (zh)	2016-06-01
RS59599B1 (sr)	2020-01-31
WO2011055303A1 (en)	2011-05-12
CA2780428C (en)	2018-02-13
ES2757882T3 (es)	2020-04-30
US8790708B2 (en)	2014-07-29
HRP20192026T4 (hr)	2023-03-31
AU2010316683A1 (en)	2012-05-24
ES3029208T3 (en)	2025-06-23
PT4066821T (pt)	2025-06-03
LTPA2025531I1 (da)	2025-09-10
EP4570242A3 (en)	2025-08-20
EP4066821A1 (en)	2022-10-05
FR25C1035I1 (fr)	2025-11-21
SI2498756T2 (sl)	2023-04-28
DK4066821T3 (da)	2025-04-14
CN102724970A (zh)	2012-10-10
SMT201900632T1 (it)	2020-01-14
FIC20250029I1 (fi)	2025-08-29
EP2498756B1 (en)	2019-09-04
US20110111018A1 (en)	2011-05-12
EP3566697B1 (en)	2024-09-11
AU2010316683B2 (en)	2015-10-08
NZ599763A (en)	2014-06-27
US20140004184A1 (en)	2014-01-02
JP5835883B2 (ja)	2015-12-24
PL2498756T3 (pl)	2020-03-31
FI2498756T4 (fi)	2023-03-22
TWI466690B (zh)	2015-01-01
RS59599B2 (sr)	2023-03-31
JP2017075192A (ja)	2017-04-20
ES2998766T3 (en)	2025-02-21
JP2015091882A (ja)	2015-05-14
FI4066821T3 (fi)	2025-05-13
HRP20250604T1 (hr)	2025-07-18
JP2011098964A (ja)	2011-05-19
ES2757882T5 (es)	2023-05-10
EP2498756B2 (en)	2023-02-15
HUE071632T2 (hu)	2025-09-28
PL4066821T3 (pl)	2025-08-11
PT2498756T (pt)	2019-11-26
LT4066821T (lt)	2025-05-12
DK2498756T4 (da)	2023-03-20
EP4066821B1 (en)	2025-03-05
AR114143A2 (es)	2020-07-29
EP4570242A2 (en)	2025-06-18
CA2780428A1 (en)	2011-05-12
PL2498756T5 (pl)	2023-04-17
US8518446B2 (en)	2013-08-27
CN103893140A (zh)	2014-07-02
AR078952A1 (es)	2011-12-14
HUE046606T2 (hu)	2020-03-30
RS66797B1 (sr)	2025-06-30
EP3566697A1 (en)	2019-11-13
SI2498756T1 (sl)	2020-01-31
CN102724970B (zh)	2014-06-25
HRP20192026T1 (hr)	2020-02-07

Publication	Publication Date	Title
DK2498756T3 (da)	2019-11-25	Tabletformuleringer af neratinibmaleat
CY2020008I1 (el)	2020-11-25	Φαρμακοτεχνικες μορφες διστρωματικου δισκιου
DK2528602T4 (da)	2020-04-27	Formuleringer af bendamustin
DK3061445T3 (da)	2023-09-11	Højkoncentrerede farmaceutiske formuleringer
BR112012011733A2 (pt)	2019-09-24	formulações de comprimido de liberação imediata
DK3097925T3 (da)	2019-08-05	Farmaceutisk sammensætning
BRPI1012539A2 (pt)	2016-03-29	composições farmacêuticas
DK3721904T3 (da)	2021-11-15	Formuleringer af t1h-antistof
BRPI1004940A2 (pt)	2018-06-19	composição farmacêutica
EP2413845A4 (en)	2015-03-18	Stent
EP2444034A4 (en)	2012-11-28	STENT
BRPI1015939A2 (pt)	2016-09-27	composição farmacêutica
BRPI1009465A2 (pt)	2015-08-18	Formulação
DK2459129T3 (da)	2019-10-07	Forbedringer af karstøtteanordninger
GT201200303A (es)	2014-04-29	Formulaciones farmacéuticas
IT1394400B1 (it)	2012-06-15	Composizioni farmaceutiche
PL2493466T3 (pl)	2021-11-15	Nowe przeciwguzowe zastosowanie kabazytakselu
DK2408446T3 (da)	2019-12-09	Anvendelse af farmaceutiske sammensætninger, der indeholder mesembrenon
DK2453858T3 (da)	2014-11-03	Fremgangsmåde
EP2478876A4 (en)	2014-07-16	STENT
SMT202100150T1 (it)	2021-05-07	Formulazioni migliorate
FR2952847B3 (fr)	2011-12-09	>
DK2501381T3 (da)	2017-11-06	Behandling af atrieflimmer
BR112012001340A2 (pt)	2016-03-15	composições farmacêuticas
BR112012003149A2 (pt)	2016-03-01	composição farmacêutica